Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2018 Oct 10. pii: molcanther.1050.2017. doi: 10.1158/1535-7163.MCT-17-1050. [Epub ahead of print]

PMID:
30305341
2.

FABP4 as a key determinant of metastatic potential of ovarian cancer.

Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK.

Nat Commun. 2018 Jul 26;9(1):2923. doi: 10.1038/s41467-018-04987-y.

3.

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122387. doi: 10.1172/jci.insight.122387. [Epub ahead of print] No abstract available.

4.

ADH1B promotes mesothelial clearance and ovarian cancer infiltration.

Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK.

Oncotarget. 2018 May 18;9(38):25115-25126. doi: 10.18632/oncotarget.25344. eCollection 2018 May 18.

5.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

6.

Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK.

Cancer Res. 2018 Jun 15;78(12):3233-3242. doi: 10.1158/0008-5472.CAN-16-1701. Epub 2018 Apr 16.

PMID:
29661830
7.

Personalized RNA Medicine for Pancreatic Cancer.

Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, Jeong JC, Muthuswamy SK, Hidalgo M, Bhatia SN, Slack FJ.

Clin Cancer Res. 2018 Apr 1;24(7):1734-1747. doi: 10.1158/1078-0432.CCR-17-2733. Epub 2018 Jan 12.

PMID:
29330203
8.

Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.

Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK.

Cell Rep. 2017 Dec 5;21(10):2785-2795. doi: 10.1016/j.celrep.2017.11.020.

9.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

PMID:
28855350
10.

Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK.

Nat Commun. 2017 Aug 21;8(1):310. doi: 10.1038/s41467-017-00411-z.

11.

Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer.

Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan V.

Clin Cancer Res. 2017 Sep 15;23(18):5611-5621. doi: 10.1158/1078-0432.CCR-16-3272. Epub 2017 Jun 13.

12.

Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.

Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw296.

13.

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Rupaimoole R, Slack FJ.

Nat Rev Drug Discov. 2017 Mar;16(3):203-222. doi: 10.1038/nrd.2016.246. Epub 2017 Feb 17. Review.

PMID:
28209991
14.

Macrophage TGF-β1 and the Proapoptotic Extracellular Matrix Protein BIGH3 Induce Renal Cell Apoptosis in Prediabetic and Diabetic Conditions.

Moritz RJ, LeBaron RG, Phelix CF, Rupaimoole R, Kim HS, Tsin A, Asmis R.

Int J Clin Med. 2016 Jul;7(7):496-510. doi: 10.4236/ijcm.2016.77055. Epub 2016 Jul 21.

15.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

16.

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK.

JCI Insight. 2016 Oct 20;1(17):e87754.

17.

Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p.

Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT.

Oncogene. 2017 Mar;36(10):1339-1350. doi: 10.1038/onc.2016.308. Epub 2016 Sep 26.

18.

A role for miR-34 in colon cancer stem cell homeostasis.

Rupaimoole R, Slack FJ.

Stem Cell Investig. 2016 Aug 24;3:42. doi: 10.21037/sci.2016.08.04. eCollection 2016. No abstract available.

19.

Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer.

Whiting N, Hu J, Zacharias NM, Lokesh GL, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya P.

J Med Imaging (Bellingham). 2016 Jul;3(3):036001. doi: 10.1117/1.JMI.3.3.036001. Epub 2016 Aug 10.

20.

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

J Clin Invest. 2016 May 2;126(5):1885-96. doi: 10.1172/JCI85086. Epub 2016 Apr 11.

21.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK.

Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169.

22.

Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.

Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK.

Mol Cancer Ther. 2016 Jun;15(6):1344-52. doi: 10.1158/1535-7163.MCT-15-0144. Epub 2016 Mar 23.

23.

miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.

Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK.

Cancer Discov. 2016 Mar;6(3):235-46. doi: 10.1158/2159-8290.CD-15-0893. Epub 2016 Feb 10. Review.

24.

Role of Increased n-acetylaspartate Levels in Cancer.

Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK.

J Natl Cancer Inst. 2016 Jan 26;108(6):djv426. doi: 10.1093/jnci/djv426.

25.

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.

Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK.

Oncogene. 2016 Aug 18;35(33):4312-20. doi: 10.1038/onc.2015.492. Epub 2016 Jan 4.

26.

Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.

Cho MS, Rupaimoole R, Choi HJ, Noh K, Chen J, Hu Q, Sood AK, Afshar-Kharghan V.

J Immunol. 2016 Feb 1;196(3):1412-8. doi: 10.4049/jimmunol.1501886. Epub 2015 Dec 30.

27.

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK.

Cell Rep. 2015 Dec 22;13(11):2395-2402. doi: 10.1016/j.celrep.2015.11.047. Epub 2015 Dec 10.

28.

Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.

Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Clin Cancer Res. 2016 Apr 1;22(7):1713-24. doi: 10.1158/1078-0432.CCR-15-1275. Epub 2015 Nov 18.

29.

Erythropoietin Stimulates Tumor Growth via EphB4.

Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK.

Cancer Cell. 2015 Nov 9;28(5):610-622. doi: 10.1016/j.ccell.2015.09.008. Epub 2015 Oct 17.

30.

Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers.

Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill SM, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukherjee S, Mills GB, Ram PT.

NPJ Syst Biol Appl. 2015 Sep 28;1:15001. doi: 10.1038/npjsba.2015.1. eCollection 2015.

31.

Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.

Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS.

Hepatology. 2016 Jan;63(1):159-72. doi: 10.1002/hep.28223. Epub 2015 Nov 26.

32.

Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.

Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Oncogene. 2016 May 5;35(18):2390-7. doi: 10.1038/onc.2015.302. Epub 2015 Aug 10.

33.

The ZNF304-integrin axis protects against anoikis in cancer.

Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G.

Nat Commun. 2015 Jun 17;6:7351. doi: 10.1038/ncomms8351.

34.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul.

35.

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK.

Clin Cancer Res. 2015 Jul 15;21(14):3286-97. doi: 10.1158/1078-0432.CCR-14-1953. Epub 2015 Apr 15.

36.

PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.

Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Jun;14(6):1466-1475. doi: 10.1158/1535-7163.MCT-14-1077. Epub 2015 Apr 1.

37.

Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB.

Cancer Cell. 2014 Dec 8;26(6):863-879. doi: 10.1016/j.ccell.2014.10.010.

38.

Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.

van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG.

Nat Commun. 2014 Oct 29;5:5203. doi: 10.1038/ncomms6203.

39.

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK.

Nat Commun. 2014 Oct 29;5:5202. doi: 10.1038/ncomms6202.

40.

Therapeutic silencing of KRAS using systemically delivered siRNAs.

Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK.

Mol Cancer Ther. 2014 Dec;13(12):2876-85. doi: 10.1158/1535-7163.MCT-14-0074. Epub 2014 Oct 3.

41.

MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.

Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W.

J Pathol. 2015 Jan;235(1):25-36. doi: 10.1002/path.4443. Epub 2014 Nov 6.

42.

Hematogenous metastasis of ovarian cancer: rethinking mode of spread.

Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK.

Cancer Cell. 2014 Jul 14;26(1):77-91. doi: 10.1016/j.ccr.2014.05.002.

43.

Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.

Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK.

Cancer Biol Ther. 2014 Aug;15(8):1061-7. doi: 10.4161/cbt.29184. Epub 2014 May 19.

44.

Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK.

Clin Cancer Res. 2014 Jun 15;20(12):3280-8. doi: 10.1158/1078-0432.CCR-14-0445. Epub 2014 Apr 22.

45.

Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.

Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK.

Mol Cancer Ther. 2014 Jul;13(7):1750-7. doi: 10.1158/1535-7163.MCT-13-0930. Epub 2014 Apr 22.

46.

Notch3 pathway alterations in ovarian cancer.

Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK.

Cancer Res. 2014 Jun 15;74(12):3282-93. doi: 10.1158/0008-5472.CAN-13-2066. Epub 2014 Apr 17.

47.

Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.

Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan S.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6. doi: 10.1073/pnas.1317242111. Epub 2014 Mar 24.

48.

Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK.

Cell Rep. 2014 Apr 24;7(2):488-500. doi: 10.1016/j.celrep.2014.03.009. Epub 2014 Apr 3.

49.

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK.

Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459.

50.

Autocrine effects of tumor-derived complement.

Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V.

Cell Rep. 2014 Mar 27;6(6):1085-1095. doi: 10.1016/j.celrep.2014.02.014. Epub 2014 Mar 6.

Supplemental Content

Loading ...
Support Center